Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6190382 | Cancer Treatment Reviews | 2016 | 11 Pages |
Abstract
Almost invariably, cervical carcinogenesis involves infection with the human papillomavirus (HPV), which inactivates part of the DNA damage response. This HPV-mediated partial inactivation of the DDR presents therapeutic targeting of the residual DDR as an interesting approach to achieve chemoradio-sensitization for cervical cancer. How the DDR can be most efficiently targeted, however, remains unclear. The fact that cisplatin and radiotherapy activate multiple signaling axes within the DDR further complicates a rational choice of therapeutic targets within the DDR. In this review, we provide an overview of the current preclinical and clinical knowledge about targeting the DDR in cervical cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hylke W. Wieringa, Ate G.J. van der Zee, Elisabeth G.E. de Vries, Marcel A.T.M. van Vugt,